MRTX News and Press, Mirati Therapeutics Inc. From 03/01/22

Cardiff has done well in a Phase 2 study using onvansertib + FOLFIRI + Avastin in treating KRAS-mutated metastatic colorectal cancer patients with a 29% objective response rate. The global market opportunity for colorectal cancer is expected to reach $17.8 billion by 2026. About 50% o...

Mirati Therapeutics, Inc. (MRTX) Q4 2021 Earnings Conference Call February 28, 2022 04:30 PM ET Company Participants Ryan Asay - Vice President of Corporate Affairs David Meek - Chief Executive Officer James Christensen - Chief Scientific Officer Ben Hickey - Chief Commercial Officer Vickie R...

The following slide deck was published by Mirati Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Mirati Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation

Mirati Therapeutics press release (NASDAQ:MRTX): Q4 GAAP EPS of -$3.72 misses by $0.79. Approx $1.5 billion in cash, cash equivalents, and short-term investments. For further details see: Mirati Therapeutics GAAP EPS of -$3.72 misses by $0.79

Mirati Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , Feb. 28, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today repo...

ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...

Shares of the clinical-stage oncology company Mirati Therapeutics (NASDAQ: MRTX) are under heavy pressure today following the U.S. Food and Drug Administration's acceptance of its New Drug Application for adagrasib as a treatment for patients with non-small cell lung cancer harborin...

At least two Street firms have cut price targets on Mirati Therapeutics (MRTX -15.1%) after the company Tuesday said its New Drug Application for its KRAS inhibitor adagrasib will get a standard 10-month review. Investors were hoping for an accelerated approval timeline of six months, wh...

Gainers: HOOKIPA Pharma (NASDAQ:HOOK) +46%. Kinnate Biopharma (NASDAQ:KNTE) +9%. Corcept Therapeutics (NASDAQ:CORT) +7%. Alkermes (NASDAQ:ALKS) +5%. Celularity (NASDAQ:CELU) +3%. Losers: Masimo (NASDAQ:MASI) -36%. Baudax Bio (NASDAQ:BXRX) -20%. ...

Mirati Therapeutics (NASDAQ:MRTX) is trading ~7% lower in the pre-market on Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) accepted its marketing application for KRASG12C inhibitor adagrasib for accelerated approval. The New Drug Application (...